Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026GlobeNewsWire · 2 days ago
Engineers Gate Manager LP Boosts Stock Position in Denali Therapeutics Inc. $DNLIDefense World · Sep 17, 2026
WINTON GROUP Ltd Decreases Position in Denali Therapeutics Inc. $DNLIDefense World · Sep 17, 2026
Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)Defense World · Sep 16, 2026
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026
BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLIDefense World · Aug 26, 2026Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.51 | -$0.68 | Miss |
| May 7, 2026 | -$0.73 | -$0.69 | Beat |
| Feb 26, 2026 | -$0.75 | -$0.73 | Beat |
| Nov 6, 2025 | -$0.76 | -$0.74 | Beat |
| Aug 11, 2025 | -$0.74 | -$0.72 | Beat |
| May 6, 2025 | -$0.71 | -$0.78 | Miss |